<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094818</url>
  </required_header>
  <id_info>
    <org_study_id>INF-04</org_study_id>
    <nct_id>NCT04094818</nct_id>
  </id_info>
  <brief_title>HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis</brief_title>
  <acronym>SEPSIS-SHIELD</acronym>
  <official_title>HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inflammatix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inflammatix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will analyze gene expression and other laboratory data from biological samples
      collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin
      &amp; soft tissue infections; or suspected sepsis of any cause.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance of HostDx Sepsis diagnostic test read-out: likelihood of bacterial infection</measure>
    <time_frame>28 Days After Enrollment</time_frame>
    <description>Percent agreement of HostDx Sepsis bacterial readout with clinical adjudication by physician 28 days after enrollment for the presence of a bacterial infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance of HostDx Sepsis diagnostic test read-out: likelihood of viral infection</measure>
    <time_frame>28 Days After Enrollment</time_frame>
    <description>Percent agreement of HostDx Sepsis viral readout with clinical adjudication by physician 28 days after enrollment for the presence of a viral infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the prognostic performance of HostDx Sepsis</measure>
    <time_frame>7 Days After Enrollment</time_frame>
    <description>Receipt of ICU-level care (including requirement for ICU transfer, mechanical ventilation, vasopressors, or renal replacement therapy (RRT))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the prognostic performance of HostDx Sepsis using number of participants requiring ICU level care</measure>
    <time_frame>5 Days</time_frame>
    <description>Composite receipt of ICU-level care (including requirement for ICU transfer, mechanical ventilation, vasopressors, or renal replacement therapy (RRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the prognostic performance of HostDx Sepsis using a composite endpoint of number of participants Hospital Mortality</measure>
    <time_frame>28 Days</time_frame>
    <description>28-Day Hospital Mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Urinary Tract Infections</condition>
  <condition>Intra-Abdominal Infections</condition>
  <condition>Skin and Soft Tissue Infection</condition>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HostDx Sepsis</intervention_name>
    <description>Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PAXgene RNA tubes containing whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the emergency departments of enrolling sites with:

          1. Suspected infection and one or more abnormal vital signs, OR

          2. Patients with suspected sepsis of any cause as defined by a blood culture order by the
             treating physician and two or more abnormal vital signs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 year

          2. Suspected Suspected acute infection (respiratory, urinary, abdominal, skin &amp;
             soft-tissue), and at least one of the symptoms OR, Suspected sepsis of any cause as
             defined by a blood culture order by the treating physician, and at least two of the
             symptoms:

               -  Heart rate: &gt;90 beats/ minute

               -  Temperature: &gt;38 C or &lt;36C

               -  Respiratory Rate: &gt;20 breaths / minutes or PaO2 of &lt;60 mmHg or SpO2 &lt;90%

               -  Systolic blood pressure: &lt;100 mmHg

               -  Altered mental status: Per clinical exam

          3. Able to provide informed consent, or consent by legally authorized representative.

        Exclusion Criteria:

          1. Patient-reported treatment with systemic antibiotics, systemic antiviral agents, or
             systemic antifungal agents within the past 7 days prior to the emergency department
             study visit. Participants will not be excluded for the following:

               -  Use of topical antibiotics, topical antiviral or topical antifungal agents

               -  Use of peri-operative (prophylactic) antibiotics

               -  Use of a single dose of antibiotics during the present ED visit (&lt;6h before blood
                  draw).

          2. Prisoners, mentally disabled, or unable to give consent. Should the patient not be
             able to provide informed consent the legally authorized representative can provide the
             consent on behalf of the patient.

          3. Previously enrolled in the present clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medstar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center - El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010 Apr;38(4):1045-53. doi: 10.1097/CCM.0b013e3181cc4824.</citation>
    <PMID>20048677</PMID>
  </reference>
  <reference>
    <citation>Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014 Aug;42(8):1749-55. doi: 10.1097/CCM.0000000000000330.</citation>
    <PMID>24717459</PMID>
  </reference>
  <reference>
    <citation>Mi MY, Klompas M, Evans L. Early Administration of Antibiotics for Suspected Sepsis. N Engl J Med. 2019 Feb 7;380(6):593-596. doi: 10.1056/NEJMclde1809210.</citation>
    <PMID>30726686</PMID>
  </reference>
  <reference>
    <citation>Singer M. Biomarkers in sepsis. Curr Opin Pulm Med. 2013 May;19(3):305-9. doi: 10.1097/MCP.0b013e32835f1b49. Review.</citation>
    <PMID>23411577</PMID>
  </reference>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? JAMA. 2012 Aug 1;308(5):502-11. doi: 10.1001/jama.2012.8262. Review. Erratum in: JAMA. 2013 Jan 23;309(4):343.</citation>
    <PMID>22851117</PMID>
  </reference>
  <reference>
    <citation>Gunsolus IL, Sweeney TE, Liesenfeld O, Ledeboer NA. Diagnosing and Managing Sepsis by Probing the Host Response to Infection: Advances, Opportunities, and Challenges. J Clin Microbiol. 2019 Jun 25;57(7). pii: e00425-19. doi: 10.1128/JCM.00425-19. Print 2019 Jul. Review.</citation>
    <PMID>31043466</PMID>
  </reference>
  <reference>
    <citation>Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med. 2015 May 13;7(287):287ra71. doi: 10.1126/scitranslmed.aaa5993.</citation>
    <PMID>25972003</PMID>
  </reference>
  <reference>
    <citation>Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med. 2016 Jul 6;8(346):346ra91. doi: 10.1126/scitranslmed.aaf7165.</citation>
    <PMID>27384347</PMID>
  </reference>
  <reference>
    <citation>Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, Bermejo-Martin JF, Almansa R, Tamayo E, Davenport EE, Burnham KL, Hinds CJ, Knight JC, Woods CW, Kingsmore SF, Ginsburg GS, Wong HR, Parnell GP, Tang B, Moldawer LL, Moore FE, Omberg L, Khatri P, Tsalik EL, Mangravite LM, Langley RJ. A community approach to mortality prediction in sepsis via gene expression analysis. Nat Commun. 2018 Feb 15;9(1):694. doi: 10.1038/s41467-018-03078-2.</citation>
    <PMID>29449546</PMID>
  </reference>
  <reference>
    <citation>Sweeney TE, Khatri P. Benchmarking Sepsis Gene Expression Diagnostics Using Public Data. Crit Care Med. 2017 Jan;45(1):1-10.</citation>
    <PMID>27681387</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>mRNA</keyword>
  <keyword>Procalcitonin</keyword>
  <keyword>C-Reactive Protein</keyword>
  <keyword>Lactate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

